Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
For the purpose of this review, GLP-1based therapies are GLP-1 receptor agonists such as exenatide, liraglutide, and others or dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin (8)
Contraindications and Precautions Because Retatrutide is still under investigation, its full contraindication profile is not completely established
The headline results at 80 weeks were: 12 mg dose: average weight loss of 28.3% (approximately 70.3 lbs / 31.9 kg) 9 mg dose: average weight loss of 25.9% (approximately 64.4 lbs / 29.2 kg) 4 mg dose: average weight loss of 19.0% (approximately 47.2 lbs / 21.4 kg) Placebo: average weight loss of just 2.2% Perhaps most striking was the proportion of patients hitting bariatric-surgery-level outcomes: at the highest dose, 45.3% of participants lost 30% or more of their body weight , and 65.3% reduced their BMI to below 30 kg/m meaning they were no longer classified as living with obesity by the end of the trial
Retatrutide is a triple GLP-1/GIP/Glucagon receptor agonist for laboratory investigation of multi-pathway incretin signalling
US$ 21.64
US$ 20.30
US$ 28.52
US$ 20.64
US$ 20.71
